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COMMENT
Ploidy dynamics increase the risk of
liver cancer initiation
Miryam Müller 1,3, Stephanie May 1,3 & Thomas G. Bird 1,2✉
Liver cancer typically arises after years of inflammatory insults to hepatocytes.
These cells can change their ploidy state during health and disease. Whilst
polyploidy may offer some protection, new research shows it may also promote
the formation of liver tumours.
In the adult human, most cells are diploid, containing a single pair of each chromosome (2n).
However, some specialised cells possess multiple complete pairs of chromosomes; a state called
polyploidy. Hepatocytes, the primary functional cell of the liver, exist in diploid and polyploid
states1. Hepatocytes increase ploidy through acytokinetic or cytokinetic mitoses, instead of
relying on cell fusion. After birth, progressively polyploid (first 4n, then ≥6n) hepatocytes are
formed. A combination of polyploid hepatocytes, varying in both nuclear and cellular poly-
ploidy, form a major fraction of the healthy adult liver; ~30% in man and >90% in mice1. Ploidy
in hepatocytes is balanced by the “ploidy conveyor” in which increasingly polyploid cells are
more likely to reduce their ploidy towards diploidy. Ploidy reduction occurs through mitosis
either bipolar or multipolar, leading to the generation of two or more daughter cells2. Despite
evidence that, in general, polyploidisation can be protective against cancer, the question of
whether it also has a darker side has remained, particularly in the formation of hepatocellular
cancer (HCC).
The liver has an exceptional regenerative capacity reflective of its exposure to repeated
hepatocellular damage due to its anatomical site and functional role in detoxification. The liver
may have evolved polyploidisation to both protect from frequent genotoxic insults and to allow
rapid regenerative flexibility. All hepatocytes can regenerate, but one rapid mechanism is
through ploidy reduction. Cellular ploidy decreases after liver resection (partial hepatectomy)
and ensuing regeneration through polyploid hepatocytes entering the M phase without prior S
phase3. Here, the reduction of multinuclear hepatocytes is balanced by the formation of
mononuclear polyploid cells4. However, chronic injury is associated with increased polyploidy.
While polyploidy is associated with cellular dysfunction and genetic instability in some cells, it
may also buffer for genetic4–7 and transcriptional8 instability. Buffering of genetic instability
occurs through the possession of multiple copies of chromosomes preventing the dominant
effect of mutation at a single genetic locus (Fig. 1). This genomic redundancy particularly
protects from loss of heterozygosity (LOH) of tumour suppressor genes.
HCC is typically a complication of chronic liver disease. Progressive genetic damage to
hepatocytes leads to activation of genetic drivers (oncogenes) or the loss of tumour suppressor
genes causing cancer formation. HCC may be either diploid or polyploid, the latter typically
associated with the loss of the p53 tumour suppressor in late-stage disease. In other cancers,
polyploidy is associated with tumour formation. However, little is known about the role that
ploidy dynamics play in HCC initiation. Ploidy reduction is rarely associated with aneuploidy9,
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and generally, ploidy reduction in hepatocytes results in faithful
chromosome segregation10. In mouse models, when ploidy is
manipulated, increasingly polyploid livers develop fewer HCC and
diploid hepatocytes are more at risk of LOH4–7. However, recently
Matsumoto et al.11 and Lin et al.12 demonstrate the importance of
ploidy dynamics in the formation of HCC in mice without directly
manipulating hepatocyte ploidy.
Lin et al. used a diethylnitrosamine (DEN)-induced carcino-
genic model to investigate the role of polyploidisation during the
transformation of hepatocytes into preneoplastic HCC lesions12.
DEN is a widely used hepatotoxin and carcinogen, inducing HCC
in rodents, albeit with debatable relevance to human HCC13.
DEN was administered perinatally causing a zonal liver injury
and mutagenic DNA adducts. The authors then observed
increased hepatocyte polyploidisation in and around areas
damaged by the carcinogen. Importantly, hepatocytes from the
injured zone formed spheres in culture and preferentially formed
tumours in a transplant assay unlike those from other areas. Foci,
reminiscent of preneoplastic foci in humans, formed within the
damaged liver. These foci contained small, presumably diploid
cells, unlike their surrounding polyploid non-neoplastic tissue.
Linking these foci to originating polyploidy hepatocytes and
resultant tumours was not possible, but these data suggest that
ploidy increase followed by reduction is associated with pre-
neoplastic foci establishment. However, the authors were able to
associate a link from early to late-stage disease mechanistically.
They found an Aurkb-driven abscission (cell separation) failure
promoted polyploid hepatocyte formation. Inhibiting Aurkb
resulted in reduced early polyploidy formation and also reduced
the formation of both preneoplastic foci and late-stage tumours;
therefore, demonstrating that polyploidisation and its subsequent
reduction promotes carcinogenesis in this model. Interestingly,
Aurkb was also overexpressed in human fatty liver disease, pro-
gressive liver fibrosis and late-stage HCC.
An elegant study by Matsumoto et al. examined ploidy
reduction in early tumourigenesis11. Here, the authors used their
novel multicolour lineage tracing system10 to trace the tumouri-
genic potential of polyploid hepatocytes alongside the ploidy
status of their progeny. In this model, upon induction of Cre-
recombinase, a reporter, which is only expressed from one
chromosome in diploid cells, expresses one of the multiple
fluorescent reporters. However, as polyploid hepatocytes possess
multiple chromosome copies, multiple different fluorescent
reporters may be co-expressed10. This enables detection, capture
and tracing of polyploid hepatocytes and their progeny over time.
Exploiting this technique, the authors examine the regenerative
and tumourigenic potential of polyploid hepatocytes in a
fumarylacetoacetate hydrolase transplant model14. In this model,
where endogenous metabolically deficient hepatocytes are out-
competed by fitter transplanted cells, they first showed that
polyploid hepatocytes frequently undergo ploidy reduction dur-
ing liver repopulation. They then show that upon repeated pro-
liferation cycles, through serial transplantation, this ability of
polyploid hepatocytes to undergo ploidy reduction was lost; a
process associated with loss of multi-nucleation. The mechanism
by which this adaptation occurs remains elusive. In tumourigenic
assays, using either introduction of oncogenes or a variety of
toxins inducing HCC, they show that bicoloured polyploid
hepatocytes often undergo ploidy reduction during early carci-
nogenesis. Moreover, when tumour suppressor loss was assessed
Fig. 1 Ploidy and loss of heterozygosity. Polyploid hepatocytes are believed to be protected from loss of heterozygosity (LOH) through the possession of
multiple copies of each chromosome. The probability of independent mutations or deletions occurring across multiple copies of each chromosome is very
rare compared to diploid cells. Loss of heterozygosity refers to the complete loss of function of a single tumour suppressor gene in all chromosomes either
by mutation or deletion after prior mutation at a single locus. Complete loss of all functional copies of a tumour suppressor gene may impose dysregulated
proliferation and tumourigenic potential. Matsumoto et al.11 and Lin et al.12 suggest that particularly for liver cancer dynamic changes in ploidy, first
polyploidisation then ploidy reduction of cells containing heterozygote loss of a tumour suppressor gene is associated with tumour initiation. Hypothetically
mis-segregation of mutant tumour suppressor genes may occur during the process of ploidy reduction leading to LOH. Typically, while chromosomes are
segregated faithfully (thick black arrow), which does not escalate the tumour risk, due to the proliferative advantage that LOH may impose even rare mis-
segregation events can have a dramatic consequence and could lead to carcinogenesis.
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in competitive tumourigenic assays, the overwhelming majority
of initiating hepatocytes underwent ploidy reduction during
cancer initiation. Overall, a striking finding was that ploidy
reduction plays a fundamental role in LOH-induced cancer.
Previous studies have shown that polyploid hepatocytes have
reduced tumourigenic potential. These two new studies show
that the situation is more complex and polyploid hepatocytes are
not protected from oncogenesis, but can promote tumour
initiation through ploidy reduction. This leads to a fundamental
question of whether some ploidy is “good” (physiological poly-
ploidy) and helps with regeneration, whereas other ploidy is
“bad” (pathological polyploidy) and has an intrinsic malignant
potential? The suggestion from Matsumoto et al. that cells can
adapt to repeated proliferation and prevent ploidy reduction
would suggest that this is indeed the case. Previous studies using
genetic perturbation to induce either increased or reduced ploidy
have linked increased polyploidy to reduced tumour risk4–7.
These new studies now suggest a mechanism through which a
change in ploidy, particularly ploidy reduction, is associated with
carcinogenesis.
Intriguingly, Matsumoto et al. show that ploidy reduction
plays a stronger role in tumour suppressor gene loss-driven
tumourigenesis than oncogene-induced carcinogenesis. The
redundant genome of polyploid cells is thought to safeguard
against LOH, protecting from malignant transformation. How-
ever, it appears that the act of ploidy reduction may invert this
protective effect. If faithful chromosome segregation were to fail,
even rarely, then ploidy reduction could easily lead to homo-
zygous loss of tumour suppressors and promote preneoplastic
foci formation (Fig. 1). Indeed, Matsumoto et al. observed
unfaithful chromosome segregation in an experiment in which
LOH occurred for an enzyme required for selective disadvantage,
possibly through aneuploidy, but potentially through miss-seg-
regation, consistent with previous studies15,16. If this is the case,
in light of the findings from these two new studies, then the
combination of a proliferative burst at a time of genetic
instability, both mutational and through multipolar mitosis,
would be particularly dangerous.
Ageing also plays a fundamental role in polyploidisation. New-
born rodent hepatocytes are diploid and polyploidisation starts
after weaning. Aurkb plays a role in failed cytokinesis typically
observed during early developmental polyploidisation17. In the
Lin et al. study, DEN was given preweaning while hepatocytes
begin polyploidisation. However, is Aurkb and a subsequent
abscission failure equally relevant for the development of HCC in
later life where polyploidisation is mostly driven by endor-
eplication? Evidence linking Aurkb overexpression in HCC to
advanced tumour stage and high-grade histology18 not only
advocates a relevance of failed cytokinesis in adult tumourigenesis
but it also suggests that tumours co-opting mechanisms seen in
early developmental polyploidisation may be more aggressive as a
result.
In adulthood, the proportion of polyploid cells in the liver is
greater in the mouse than in human. Therefore, findings from
rodent models may over-interpret the human relevance of
ploidy-related tumourigenesis. Nonetheless, these are important
models and the idea put forward by Matsumoto et al. that
prolonged proliferation stabilises polyploid cells prevents ploidy
reduction and reduces malignant transformation is intriguing.
Dissecting the mechanism through which this occurs might
uncover therapeutic opportunities for the prevention of HCC.
Similarly, the processes discussed above could serve as bio-
markers for future cancer risk. In summary, both polyploidisa-
tion and, in particular, ploidy reduction carries the potential for
malignant transformation, and yet both processes have clearly
been selected for maintaining liver physiology. These new stu-
dies have shed new light on this topic highlighting a potentially
critical role for tumour formation in the liver by ploidy
reduction.
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